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Prostacyclin is a naturally occurring eicosanoid that pos-sesses anti-inflammatory and anti-metastatic properties
and has a suppressive role in tumor growth.1 Prostacyclin
synthase (PGIS) is the final committed enzymatic step in the
pathway of PGI2 production, occurring at a branch point
where substrate can be directed toward either PGI2, throm-
boxane A2 (TxA2), or prostaglandin E2 (PGE2) (Figure 1).
Eicosanoid production and balance is proving pivotal in lung
tumorigenesis.
THE BIOLOGY OF PROSTACYCLIN
Prostacyclin (PGI2) is a lipid mediator derived through
the cyclo-oxygenase (COX) pathway. The cascade leading to
the production of PGI2 is shown in Figure 1. Phospholipase
A2 (PLA2) cleaves arachidonic acid from lipid bilayers to
form free fatty acids. It is generally believed that rate-limiting
steps in the arachidonic acid cascade occur at both arachi-
donic acid formation and the formation of prostaglandin H2
(PGH2) by prostaglandin H2 synthases (more commonly
known as COX-1 and COX-2).2 There are two PGH synthase
isozymes called COX-1 and COX-2. Each enzyme is coded
by a different gene and is under separate regulatory control.3
PGI2 is one of the main products of arachidonic acid in
all vascular tissues tested to date.4 Once released from cells,
PGI2 acts as an autocrine and paracrine effector to regulate
the function of various differentiated cells and platelets.
Prostacyclin has many important biologic effects. It is the
most potent endogenous inhibitor of platelet aggregation yet
discovered,4 and as a product of the vascular wall endothe-
lium and smooth muscle cells, PGI2 produces vasodilation of
all vascular beds studied.5 PGI2 also inhibits both prolifera-
tion and DNA synthesis in smooth muscle cells.6
PROSTACYCLIN SIGNALING AND REGULATION
As illustrated in Figure 1, there are two documented
signaling pathways for prostacyclin. The first is through its
well-described membrane receptor (IP), and the second is at
the nuclear membrane via the peroxisome-proliferator acti-
vated receptors (PPARs).7 The IP is a single canonical cell
membrane-specific seven-transmembrane domain G protein-
coupled receptor that has been cloned and characterized,8
with ligand binding resulting in G protein activation and
stimulation of adenyl cyclase (thereby increasing intracellular
cAMP).9 PPARs are members of the nuclear hormone recep-
tor superfamily that act as ligand-activated transcription fac-
tors. Three isoforms have been identified: PPAR, , and
–-all of which bind to specific DNA sequences as het-
erodimers with the retinoic acid X-receptors and regulate
gene transcription.10 PPAR expression is increased in lung
cancer and may play a critical role in malignant transforma-
tion.11 Eicosanoids, like prostacyclin, are ligands for the
PPAR promoter responsive element7 and can modify PPAR
activity. Prostacyclin analogues can activate the PPAR re-
ceptor and have been shown to inhibit the growth of A549
non-small cell lung cancer (NSCLC) cell lines.12 PGIS and
PGI2 may also affect PPAR activity. Our laboratory has
shown that lung-specific PGIS overexpression results in a
nearly twofold induction of PPAR expression,13 and PPAR
activation by ligands (like the synthetic thiazolidinediones)
results in growth arrest of human NSCLC cell lines.14
The regulation of prostacyclin production has been an
area of concentrated research, and plasma lipoproteins, TxA2
analogues, vitamin D3, and plant sterols have all been shown
to induce in vitro prostacyclin production.15–17 Variations in
the PGIS promoter may affect PGI2 synthesis, and the pro-
moter contains highly GC-rich regions and multiple putative
AP1 and SP2 transcription factor binding sites.18 Addition-
ally, a variable number of tandem repeats, varying from three
to seven base pairs in length, in the proximal promoter have
been correlated with low and high pulse pressures in a
Japanese cohort.19 PGIS promoter polymorphisms in lung
cancer and chronic obstructive pulmonary disease are cur-
rently being actively investigated by our group.
PROSTACYCLIN AND LUNG CANCER
CHEMOPREVENTION
Based on its anti-inflammatory and anti-metastatic ef-
fects and its suppressive role in tumor growth, we studied
prostacyclin as a lung cancer chemopreventive agent. Com-
parative immunohistochemical analyses of NSCLC and nor-
mal human lung tissue focusing on the COX pathway have
shown that tumors are typically positive for TxA2 synthase,
PGD2 synthase, and PGE2 synthase, but negative for PGIS.20
Gene expression analysis of NSCLC shows that PGIS content
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in human lung adenocarcinomas (AC) is usually down-regu-
lated while PGES content rises.21 However, a small subset of
patients with AC whose lung tumors retained PGIS expres-
sion survived significantly longer.21 Furthermore, murine
lung tumor cells lines produce more PGE2 and less PGI2 than
non-tumorigenic cell lines.22 In preclinical chemoprevention
studies, we have shown that selective pulmonary PGIS over-
expression protects against murine lung tumorigenesis in a
variety of murine tumorigenesis models, including tobacco
smoke exposure.13,23 The beneficial effects of PGIS overex-
pression could be the result of either higher levels of PGI2 or
lower levels of PGE2 as a result of depletion of the precursor
substrate PGH2. In the multiple carcinogenesis models ap-
plied to the PGIS overexpressing animals, elevation of PGI2
(not decreases in PGE2) was consistently required for che-
moprevention to occur.
Based on the preclinical studies summarized above, the
National Cancer Institute is currently funding the Lung Can-
cer Biomarker and Chemoprevention Consortium to conduct
a multicenter study investigating the use of Iloprost (an oral
prostacyclin analogue) for lung cancer chemoprevention.
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